Longeveron stem cell therapy data to be presented at 2026 AAIC

June 18, 2026 9:20 AM

Longeveron Inc. (NASDAQ: LGVN) announced that additional analysis of Phase 2a clinical trial data for its stem cell therapy laromestrocel ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found